MedTrace Logo

The Gut-Skin Axis Integrity in Psoriatic Patients

NCT04212507 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2020-07-09

No results posted yet for this study

Summary

Assess two non-invasive markers of intestinal barrier integrity {Claudin-3 and intestinal Fatty acid-binding protein (I-FABP)} in patients with psoriasis and to evaluate the possible relation of these markers with the demographic and clinical data.

Conditions

  • Psoriatic Patients

Interventions

DIAGNOSTIC_TEST

The serum level of Claudin-3 and intestinal Fatty acid binding protein

The serum level of Claudin-3 and intestinal Fatty acid-binding protein between patients with psoriasis and controls Understanding the interplay between microbiota, gut barrier and inflammation may contribute to the development of new methods of preventing onset or exacerbations of psoriasis and new therapeutic approach for psoriasis.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-12-01
Completion
2021-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04212507 on ClinicalTrials.gov